Microsphere-Based Methods for Detecting HIV Antibodies from International AIDS Vaccine Initiative

 
 
BioResearch Open Access
BioResearch Open Access
 
Spread the Word
Listed Under

Tags:
BioResearch Open Access
Robert Lanza
Biotechnology
Hiv Aids
HIV antibodies

Industrys:
Biotech
Medical

Location:
New Rochelle - New York - US

Subject:
Reports

NEW ROCHELLE, N.Y. - May 23, 2013 - PRLog -- Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext. 2156, vcohn@liebertpub.com

New Microsphere-Based Methods for Detecting HIV Antibodies from the International AIDS Vaccine Initiative

New Rochelle, NY—Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies and can measure even small amounts of multiple antibodies at one time. This novel multiplex immunoassay approach is described in an article in BioResearch Open Access, a peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com). The article is available on the BioResearch Open Access website (http://www.liebertpub.com/biores).

The ability to detect very low levels of HIV virus is critical for early detection of HIV infection and to assess the effectiveness of an AIDS vaccine. Rebecca L.R. Powell and coauthors from the International AIDS Vaccine Initiative, Brooklyn, NY, compared the microsphere-based BioPlex® Suspension Array System to conventional ELISA antibody test methods for detecting simian immunodeficiency virus (SIV) in SIV-infected rhesus macaques.

The specificity of the two methods were comparable. The microsphere-based test system successfully detected four key HIV antibodies simultaneously in SIV-infected animals, compared to noninfected control animals. Furthermore, in blood samples that tested negative for one or more HIV antibody using an ELISA test, the microsphere assay was often able to detect the antibody in the sample.

The findings were presented in the article “A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239." (http://online.liebertpub.com/doi/full/10.1089/biores.2013...)

"This new method provides a significant improvement over standard ELISA techniques, allowing increased sensitivity for specific antibody detection—which is highly important for assessing vaccine efficacy," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

About the Journal
BioResearch Open Access
is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website (http://www.liebertpub.com/biores).

About the Publisher
Mary Ann Liebert, Inc., publishers
, is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including, AIDS Research and Human Retroviruses, Tissue Engineering, Stem Cells and Development, and Human Gene Therapy. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com).
End
Source:
Email:***@liebertpub.com Email Verified
Phone:914-740-2100
Tags:BioResearch Open Access, Robert Lanza, Biotechnology, Hiv Aids, HIV antibodies
Industry:Biotech, Medical
Location:New Rochelle - New York - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Mary Ann Liebert, Inc., publishers PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share